More Articles...
- Use of Generic Antiretrovirals for Treatment of HIV in the United States
- Emerging Issues in Clinical Trials for New ARV Development
- Review of Cardiovascular Disease in HIV Treatment
- Global Surveillance of Antiretroviral Drug Safety
- 2009 Update on Rethinking Approaches to Expanded Access Programs
- HIV Diagnostic and Monitoring Technologies in Resource Limited Settings
- Standardization and Clinical Relevance of HIV Drug Resistance Testing
- Adherence to HIV Therapy
- ARV Drugs, Adverse Events, Case Definition, Grading, Laboratory Diagnosis and Treatment Monitoring
- Re-Thinking the Design of Clinical Trials for the Development of New ARVs
- Rethinking the Approach to Expanded Access Programs
- HIV-TB Co-Infection: Meeting the Challenge
- Chemokine Antagonist Working Group
- Workshop on Quantitative Methods for Research on Antiviral Resistance
- Pediatric Diagnosis and Monitoring Working Group
- Long-Term Monitoring of Treatment Related Adverse Events in the Resource Limited Setting
- Accessing Drugs for Clinical Research in Resource Limited Settings
- HIV/TB Co-Infection
- Pediatric Formulations for Antiretroviral Therapies
- Regulatory Considerations for the Treatment of Lipodystrophy Roundtable Discussion
- Surveillance of HIV Drug Resistance in North America
- HIV Monitoring Technologies for Resource-Limited Settings Symposium XV International AIDS Conference
- Salvage Therapy II
- Transfer of HIV Diagnostic & Monitoring Technologies to Resource-Poor Settings
- HIV Infection, Treatment & Risk for Cardiovascular Disease
- HIV Therapeutic Vaccines — Moving the Field Forward
- Making Sense of the Lipodystrophy Studies
- Protein Binding in Antiretroviral Therapies
- Monitoring Long-Term Toxicities of HIV Treatments
- Importance of Antiretroviral Drug Levels in Sanctuary Sites and Viral Reservoirs
- 3rd International Workshop on Structured Treatment Interruption
- Immune-based Therapies
- Anti-viral Therapy and Salvage Therapy
